Inmed Pharmaceuticals In (IN.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 06/30
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Cash Flows From Operating Activities | |||||
| Depreciation Amortization | 149 | 147 | 149 | 154 | 153 |
| Accounts receivable | -89 | -92 | 73 | -17 | -20 |
| Other Working Capital | 142 | -955 | 511 | -1,267 | -2,113 |
| Other Operating Activity | -1,859 | -1,814 | -2,988 | -2,917 | -3,369 |
| Operating Cash Flow | $-1,657 | $-2,713 | $-2,256 | $-4,047 | $-5,349 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -128 | N/A | N/A | 0 | -4 |
| Net Acquisitions | 0 | N/A | N/A | -300 | 0 |
| Other Investing Activity | 0 | -500 | 0 | -425 | 0 |
| Investing Cash Flow | $-128 | $-500 | $0 | $-725 | $-4 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | 0 | N/A | N/A | 396 | -29 |
| Common Stock Issued | 0 | 6,000 | 6,000 | 5,146 | 0 |
| Other Financing Activity | -64 | -685 | -571 | -491 | 0 |
| Financing Cash Flow | $-64 | $5,315 | $5,429 | $5,051 | $-29 |
| Beginning Cash Position | 11,453 | 9,350 | 6,177 | 5,898 | 11,280 |
| End Cash Position | 9,604 | 11,453 | 9,350 | 6,177 | 5,898 |
| Net Cash Flow | $-1,849 | $2,102 | $3,174 | $279 | $-5,382 |
| Free Cash Flow | |||||
| Operating Cash Flow | -1,657 | -2,713 | -2,256 | -4,047 | -5,349 |
| Capital Expenditure | N/A | N/A | N/A | N/A | -4 |
| Free Cash Flow | -1,657 | -2,713 | -2,256 | -4,047 | -5,352 |